Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Hardy-Werbin, Max; Rocha, Pedro; Arpí, Oriol; Taus, Álvaro; Nonell, Lara; Durán, Xavier; Villanueva, Xavier; Joseph-Pietras, Deborah; Nolan, Luke; Danson, Sarah; W. Griffiths, Richard; López‐Botet, Miguel; Rovira, Ana; Albanell, Joan; H. Ottensmeier, Christian; Arriola, Edurne

doi:10.1080/2162402x.2019.1593810

Public

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Published in OncoImmunology • Mar 27, 2019

Authors:

Max Hardy-Werbin

Pedro Rocha

Oriol Arpí

Abstract

Background. Immunotherapy has shown efficacy in small cell lung cancer (SCLC), but only a subset of patients benefits. Surrogate biomarkers are urgently needed. Our aim was to evaluate serum Th1, Th2, and proinflammatory cytokines in two cohorts of SCLC patients before and during treatment with chem...

Subject

Ipilimumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!